Laurus Labs Q4 FY26 consensus: Rs 1,620 cr revenue

What analysts are pencilling in for Q4 FY26

Analyst consensus estimates suggest Laurus Labs may close Q4 FY26 with revenue of Rs 1,620 crore, implying about 9% year-on-year growth. Profit after tax (PAT) is estimated at Rs 145 crore, which would be about 23% higher than the same quarter of FY25. The estimates are framed as a read-through of both the broader pharma sector setup and the company’s operating momentum seen in prior quarters.

Alongside the profit estimate, the street is also tracking margin movement closely. Consensus expects an EBITDA margin of around 8.9%, described as an improvement versus the year-ago quarter, led by operating leverage and cost efficiencies.

Sector context: why Q4 FY26 is being watched

The pharma sector is expected to deliver a solid Q4 FY26, supported by stabilising US generic pricing, robust domestic formulation growth, and a deepening complex generics pipeline. These factors are viewed as supportive for both revenue and margin expansion across companies.

For Laurus Labs, the consensus view in the provided estimates is built on this sector backdrop as well as company-specific execution over recent quarters. While the estimates do not provide segment-level splits for Q4 FY26, the sector commentary highlights where the market believes incremental growth and margin support could come from.

Q3 FY26 base and Q4 FY26 estimated step-up

Consensus also provides a point of comparison with the immediately preceding quarter. Q3 FY26 actuals referenced in the dataset show revenue of Rs 1,480 crore and PAT of Rs 118 crore, with a PAT margin of 8.0%. Against this base, Q4 FY26 is modeled higher on both revenue and profit.

In dividend-related data, the table includes dividend history of Rs 2.00 per share and repeats a final dividend expectation of Rs 3.00. The dataset does not specify the year for the expected final dividend line, but it appears as part of the same summary set.

Recent reference point: Q4 FY25 performance that shaped sentiment

In March 2025 quarter (Q4 FY25), Laurus Labs reported revenue from operations of Rs 1,720 crore, up 19% year-on-year versus Rs 1,440 crore in the year-ago period, as per the provided update. The same update notes R&D spending of Rs 66 crore, stated as 3.7% of revenue.

On profits, the dataset carries multiple figures for Q4 FY25 from different report lines: net profit cited at about Rs 233.6 crore to Rs 234 crore, compared with Rs 75.6 crore to Rs 76 crore in the year-ago quarter. EBITDA is also cited in two ways: Rs 419 crore with margin 24.5%, and Rs 477 crore with margin 27.7%, with the latter explicitly stated to include a one-time gain of Rs 59 crore from sale of land.

Share price moves: the stock has been sensitive to news flow

The dataset describes a sharp intraday move around results and broader market weakness. Laurus Labs fell to an intraday low of Rs 606.5 (about 6% down), and at 11:58 AM it was quoted at Rs 618.50, down 4.18% from the previous close of Rs 645.50. Over the same time, the Nifty50 was at 23,873.55, down 373.15 points (1.54%).

It also notes the stock was about 8% below its 52-week high of Rs 660.9 (touched on September 06, 2024). Market capitalisation is stated at Rs 33,352.77 crore, and the stock is described as up about 7% year-to-date, compared with a 2.5% rise in the Nifty50.

What brokerages have highlighted in the cycle so far

MOFSL is mentioned as maintaining a ‘Buy’ rating with a revised target price of Rs 750, in the context of the company delivering a second consecutive quarter with better-than-expected performance driven by traction in the Formulation (FDF)/API segment. The same note flags that CDMO performance was weak in the March 2025 quarter, while the sales run rate continued to improve.

Antique Stock Broking is cited as pointing to 95% year-on-year growth in the small molecules CDMO business during Q4 FY25. The brokerage commentary also includes a margin trajectory expectation: potential improvement in EBITDA margin to 26% in FY27E, versus 19% in FY25, linked to enhanced CDMO capacity utilisation and operating leverage. The same note flags ARV exposure, stating ARV represents 46% of FY25 revenue and 34% of FY27E revenue, with a best-case scenario of flat revenue over FY25-27E. It also notes management did not provide specific growth guidance for the CDMO segment.

Market impact: what the Q4 FY26 estimate implies for investors

If consensus plays out, the market will read Q4 FY26 primarily through the lens of two numbers: revenue growth of about 9% and PAT growth of about 23%. The gap between revenue growth and profit growth implies expectations of better profitability, consistent with the dataset’s margin improvement callout to around 8.9% EBITDA margin.

The stock’s recent pattern in the dataset shows meaningful price sensitivity around earnings and macro headlines. Examples included in the text range from a 4% fall despite a reported 886% surge in Q2 PAT to Rs 195 crore, to a 15% drop amid reports of US foreign aid suspension. That context matters because Q4 FY26 estimates may set a clear “beat or miss” bar for near-term stock reaction.

Analysis: key swing factors embedded in the consensus

The sector narrative supplied with the estimates points to three broad drivers: pricing stability in US generics, domestic formulation strength, and complex generics pipelines. For Laurus Labs, the operational angle within the estimate is the expectation of operating leverage and cost efficiencies, which are cited as reasons for the margin improvement.

At the same time, the dataset’s brokerage commentary underscores that segment mix and utilisation can meaningfully affect margins, as seen in Q4 FY25 where EBITDA and EBITDA margin were also discussed alongside a one-time gain. As a result, investors typically separate reported margin from any one-offs when comparing quarter-to-quarter performance.

What to track next

The Q4 FY26 consensus numbers set a reference point of Rs 1,620 crore revenue and Rs 145 crore PAT, with margin expected near 8.9%. In the near term, the market will likely compare reported results against these estimates, alongside any updates on business momentum that align with the sector theme of improving pricing and product complexity.

Separately, dividend expectations are part of the dataset, including the mention of a Rs 3.00 final dividend expected, which may also be watched when the company communicates shareholder-return decisions.